Trastuzumab for the Treatment of Salivary Duct Carcinoma

OBJECTIVES. Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with high mortality and poor response to treatment. A significant fraction of SDCs are HER2 positive. This retrospective review examines HER2 testing in SDC and the outcome of trastuzumab-based therapy in adjuvant and pall...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Limaye, Sewanti A., Posner, Marshall R., Krane, Jeffrey F., Fonfria, Maria, Lorch, Jochen H., Dillon, Deborah A., Shreenivas, Aditya V., Tishler, Roy B., Haddad, Robert I.
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2013
Materias:
Head and Neck Cancers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607526/
https://ncbi.nlm.nih.gov/pubmed/23429737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0369
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares